Copyright
©The Author(s) 2015.
World J Gastroenterol. Aug 21, 2015; 21(31): 9262-9272
Published online Aug 21, 2015. doi: 10.3748/wjg.v21.i31.9262
Published online Aug 21, 2015. doi: 10.3748/wjg.v21.i31.9262
ClinicalTrials.gov Identifier | Title | Design/phase | Intervention | Primary purpose |
NCT01294072 | Study investigating the ability of plant exosomes to deliver curcumin to normal and colon cancer tissue | Phase I | Dietary supplement: curcumin Dietary supplement: curcumin conjugated with plant exosomes Other: no intervention | Treatment |
NCT00295035 | Phase III trial of gemcitabine, curcumin and celebrex in patients with metastatic colon cancer | Phase III | Drug: celecoxib Drug: curcumin | Treatment |
NCT00027495 | Curcumin for the prevention of colon cancer | Phase I | Dietary supplement: curcumin | Prevention |
NCT00973869 | Curcumin in preventing colorectal cancer in patients undergoing colorectal endoscopy or colorectal surgery | Phase I | Dietary supplement: curcumin Other: high performance liquid chromatography Other: laboratory biomarker analysis Other: pharmacological study Procedure: diagnostic endoscopic procedure Procedure: therapeutic conventional surgery | Prevention |
NCT00365209 | Phase IIA trial of curcumin among patients with prevalent subclinical neoplastic lesions (aberrant crypt foci) | Phase II | Other: laboratory biomarker analysis Other: pharmacological study Drug: curcumin | Prevention |
NCT01490996 | Combining curcumin with FOLFOX chemotherapy in patients with inoperable colorectal cancer | Phase I Phase II | Drug: oral complex C3 curcumin+ chemotherapy Drug: chemotherapy only | Treatment |
NCT01859858 | A prospective evaluation of the effect of curcumin on dose limiting toxicity and pharmacokinetics of irinotecan in patients with solid tumors | Phase I | Dietary supplement: curcumin Drug: Irinotecan | Basic science |
NCT00118989 | Curcumin for the chemoprevention of colorectal cancer | Phase II | 4 g curcumin daily for 4 mo or placebo | Prevention |
NCT00256334 | Resveratrol for patients with colon cancer | Phase I | Drug: resveratrol | Treatment |
NCT00578396 | Phase I biomarker study of dietary grape-derived low dose resveratrol for colon cancer prevention | Phase I | Dietary supplement: grapes | Prevention Phase I |
NCT00433576 | Resveratrol in treating patients with colorectal cancer that can be removed by surgery | Phase I | Patients with colorectal adenocarcinomas received resveratrol for days 1 to 8 and on day 9 underwent colorectomy Tumor biopsy will be retrieved |
- Citation: Li YH, Niu YB, Sun Y, Zhang F, Liu CX, Fan L, Mei QB. Role of phytochemicals in colorectal cancer prevention. World J Gastroenterol 2015; 21(31): 9262-9272
- URL: https://www.wjgnet.com/1007-9327/full/v21/i31/9262.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i31.9262